Results 51 to 60 of about 39,387 (293)
Background: Cardiovascular disease (CVD) is the leading cause of death globally. The use of antiplatelets in the secondary prevention of CVD is well established. Their role in primary prevention of CVD is uncertain.
Uzoma Chukwunonso Okechukwu +2 more
doaj +1 more source
Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset [PDF]
<p><b>Background and Purpose:</b> Antiplatelets (APs) may increase the risk of symptomatic intracerebral hemorrhage (ICH) following intravenous thrombolysis after ischemic stroke.</p> <p><b>Methods:</b> We ...
Ahmed, N. +10 more
core +2 more sources
This study identifies Rubicon as a key platelet protein that bidirectionally regulates GPVI and integrin αIIbβ3 signaling. Platelet Rubicon protects against cerebral ischemia‐reperfusion injury by limiting infarction without increasing hemorrhage.
Xiaoyan Chen +11 more
wiley +1 more source
Background/Objectives: This paper evaluates the incidence of thrombotic and/or hemorrhagic adverse events within 30 days after oral health procedures (OHPs) in patients taking antithrombotic agents.
María González-Zamora +12 more
doaj +1 more source
Clinical and pharmacological analysis of patients with acute coronary syndrome under 45 years of age: A prospective cohort study [PDF]
Background/Aim: Acute coronary syndrome (ACS) in young people is a problem of growing concern. There is an increasing need to evaluate this disease and predict its sequelae for better prevention and management.
Badai Nashtar Saad +3 more
doaj +1 more source
Abstract Number ‐ 157: Effect of Antiplatelet Therapy in Acute Ischemic Stroke with Tandem Lesions
Introduction Recent studies have shown beneficial effects of Carotid artery stenting (CAS) in acute ischemic stroke patients with tandem lesions (TL). However, stent placement requires the use of antiplatelet medications to prevent in‐stent thrombosis ...
Mudassir Farooqui +44 more
doaj +1 more source
Silence of the limbs: pharmacological symptomatic treatment of intermittent claudication [PDF]
Several oral "vasoactive" drugs claim to increase walking capacity in patients with intermittent claudication (IC). Naftidrofuryl, cilostazol, buflomedil, and pentoxifylline are the most studied molecules.
De Backer, Gui +4 more
core +1 more source
ABSTRACT Background With population aging and extended healthy life expectancy, the management of acute cholecystitis (AC) in patients aged ≥ 85 years has evolved. However, the Tokyo Guidelines 2018 (TG18) for AC provide no specific risk assessment criteria for this population.
Yuta Kobayashi +9 more
wiley +1 more source
Antiplatelet treatment of acute coronary syndromes: novel clinical and translational perspectives [PDF]
Filippo Crea
openalex +1 more source
Anti‐inflammatory drugs may be effective in improving recurrence‐free survival after radical gastrectomy in patients with pStage II or III gastric cancer. ABSTRACT Background Elevated postoperative inflammation is associated with reduced recurrence‐free survival (RFS) after gastrectomy in patients with gastric cancer, independent of postoperative ...
Ryota Matsui +7 more
wiley +1 more source

